In a discovery recently published in Nature, MIT chemists led by Professor Alison Wendlandt have developed a precision ...

Beyond the rather low efficiency of today’s solar panels in converting the power of the sun into electricity, the ...

ACCG-2671 is an oral small molecule amylin receptor agonist which acts through complementary satiety pathways in the ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

A study in the Chinese Journal of Natural Medicines reports the first high-resolution structure of the major G-quadruplex in the TMPRSS2 promoter and shows how berberine binds and stabilizes it, ...

Structure Therapeutics (NASDAQ:GPCR) shared new top-line results from its ACCESS II clinical program for aleniglipron, an ...

Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety signals. Read more on GPCR stock.

When methylone was finally banned in 2011, unregulated chemists simply tweaked the molecule to evade the ban, creating new ...

Structure Therapeutics (NasdaqGM:GPCR) reported positive topline Phase 2 results for its oral GLP-1 receptor agonist ...

When chemists design drug candidates, shape matters enormously. Many active pharmaceutical ingredients contain branched ...

While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule ...